Fredun Pharmace Q3 FY26 sales up 57% to Rs 159.93 cr

Key update from the December 2025 quarter

Fredun Pharmaceuticals Ltd (Fredun Pharmace) reported a sharp year-on-year rise in standalone revenue and profitability for the quarter ended December 2025. Standalone net sales came in at Rs 159.93 crore, up 57.04% from Rs 101.84 crore in December 2024. Profitability strengthened alongside revenue, with net profit, EBITDA and earnings per share also showing strong YoY growth. The numbers are being tracked closely given the company’s recent run of quarterly sales growth across FY25 and FY26. The update adds fresh data points for investors following the small and midcap pharmaceuticals space.

Headline financials: sales, profit, EBITDA and EPS

For the December 2025 quarter, Fredun Pharmace reported standalone net profit of Rs 10.48 crore. This was up 96.49% compared with Rs 5.33 crore in December 2024. EBITDA stood at Rs 26.33 crore, rising 99.02% from Rs 13.23 crore a year earlier. The company’s standalone EPS increased to Rs 22.19 in December 2025 from Rs 11.29 in December 2024. These are the core reported quarterly figures referenced in the update.

How the year-on-year comparison shaped up

The YoY comparison indicates that growth was broad-based across both the top line and operating profitability. Net sales rose by Rs 58.09 crore between December 2024 and December 2025, based on the reported figures. Over the same period, net profit increased by Rs 5.15 crore and EBITDA increased by Rs 13.10 crore. The EPS change broadly mirrored the improvement in profit, rising by Rs 10.90 year-on-year. While the underlying drivers were not detailed in the data provided, the magnitude of the YoY shifts places this quarter among the stronger recent comparisons for the company.

A look at the recent quarterly sales trend in FY25 and FY26

The update also lists multiple quarters of standalone net sales growth, offering a quick view of recent momentum. For March 2025, standalone net sales were reported at Rs 165.44 crore, up 40.16% YoY. For June 2025, net sales were Rs 119.40 crore, up 54% YoY. For September 2025, net sales were Rs 143.59 crore, up 34.33% YoY. For December 2025, net sales were Rs 159.93 crore, up 57.04% YoY.

Snapshot from the Jun 2025 vs Mar 2025 quarterly table

Separate quarterly line items were also provided for June 2025 and March 2025, highlighting changes in income, costs, and margins. Total income was listed at Rs 119.86 crore in June 2025 versus Rs 167.41 crore in March 2025. Total expenses were Rs 104.28 crore in June 2025 compared with Rs 152.00 crore in March 2025. EBIT was reported at Rs 15.57 crore in June 2025 and Rs 15.41 crore in March 2025, while PAT was Rs 6.77 crore in June 2025 and Rs 6.00 crore in March 2025. EBIT margin was shown at 12.99% for June 2025 versus 9.21% for March 2025, and net profit margin at 5.64% versus 3.59%.

Share price move: what the update said

The share price section in the update reported a modest uptick in the stock. Fredun Pharmaceuticals’ share price was stated to have moved up by 0.96% from its previous close of Rs 1,723.30. The stock’s last traded price was listed at Rs 1,740.00. This price movement is a point-in-time update and does not, by itself, indicate the market’s full reaction to the quarterly numbers. Still, it provides context for where the stock was trading around the time of the reported data.

Business profile and product coverage

Fredun Pharmaceuticals was described as being established to produce drugs of international standards at affordable prices. The company’s manufacturing coverage includes allopathic formulations such as tablets, syrups, capsules, and ointments. Therapeutic areas listed include anti-bacterial, anti-malarial and anti-diabetic products, and also anti-retrovirals and anti-hypertensives. The update also notes expansion into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products. This expansion is described as being through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.

Long-term growth metrics mentioned in the note

Alongside the quarterly figures, the note included a few longer-term growth observations. It stated that the company has delivered profit growth of 61.4% CAGR over the last five years. It also stated that the company’s median sales growth is 26.8% over the last 10 years. The note further included a line that the “company is expected to give good quarter,” which is an expectation rather than a reported outcome. Investors typically compare such long-term metrics with quarterly volatility to assess consistency, but the update itself does not provide additional breakdowns behind these summary growth figures.

Key identifiers and office details listed

The update included certain company identifiers and contact details. The BSE scrip code was listed as 539730, and the ISIN was stated as INE194R01017. The registered office address was listed as “URMI ESTATE, 11th Floor, Ganpatrao Kadam Marg, Mumbai, Maharashtra 400013,” along with telephone and fax numbers and email. A separate Mumbai address and contact details were also provided in the text. These details are typically used for corporate reference and investor communication rather than financial analysis.

Why the quarter matters for investors tracking pharma earnings

For investors tracking quarterly earnings, the December 2025 standalone result stands out for the combination of strong revenue growth and a near doubling in EBITDA and net profit on a YoY basis. The EPS growth reported for the quarter also aligns with the improvement in profitability. The recent sequence of quarterly sales growth rates listed for March, June, September and December adds context to the company’s FY25 and FY26 trajectory. However, the update does not provide segment splits, product-level drivers, or management commentary, so analysis is limited to the reported financial outcomes. The next set of quarterly disclosures will be important to verify whether the pace of YoY growth sustains and how margins behave across cycles.